Novavax (NVAX) Depreciation & Amortization (CF) (2010 - 2026)

Novavax's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 63.29% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $22.3 million (down 50.02% YoY), while the FY2025 annual figure was $27.6 million, down 43.06% from the prior year.
• Depreciation & Amortization (CF) was $3.1 million for Q1 2026 at Novavax, down from $5.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $12.7 million in Q3 2024 to a low of $3.1 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $8.8 million across 5 years, with a median of $8.3 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 191.97% in 2022, then slumped 63.29% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $7.2 million in 2022, then soared by 49.46% to $10.8 million in 2023, then advanced by 15.96% to $12.5 million in 2024, then tumbled by 59.06% to $5.1 million in 2025, then plunged by 40.25% to $3.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $3.1 million (Q1 2026), $5.1 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.